IPHA Innate Pharma SA Forecast, Technical & Fundamental Analysis

IPHA in upward trend: price may jump up because it broke its lower Bollinger Band on March 31, 2025

IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where IPHA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on IPHA as a result. In of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on April 14, 2025. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for IPHA moved above the 200-day moving average on April 24, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where IPHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

IPHA moved below its 50-day moving average on April 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IPHA crossed bearishly below the 50-day moving average on March 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IPHA entered a downward trend on April 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.584) is normal, around the industry mean (14.255). P/E Ratio (0.000) is within average values for comparable stocks, (63.920). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.829). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (11.211) is also within normal values, averaging (254.270).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.